Upadacitinib for treating moderate to severe rheumatoid arthritis – consultation appraisal document

In this DRAFT guidance, upadacitinib, with methotrexate is recommended in adults whose disease has responded inadequately to intensive therapy with a combination of conventional disease-modifying antirheumatic drugs, only if disease activity score is > 5.1.


National Institute for Health and Care Excellence